841 results on '"Mitsikostas, Dimos"'
Search Results
2. The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution: from headache burden to a global action plan for headache disorders
Catalog
Books, media, physical & digital resources
3. Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence
4. Evidence-based symptomatic treatment of migraine
5. Instrumental Occlusal Analysis in Migraine Patients: A Quantitative Cross Sectional Study
6. Headache disorders in multiple sclerosis: Is there an association? A systematic review and meta-analysis
7. Nocebos in migraine
8. Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030
9. COVID-19 vaccination-related headache showed two different clusters in the long-term course: a prospective multicenter follow-up study (COVA-Head Study)
10. A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod
11. Meta-analysis of placebo-arm dropouts in osteoporosis randomized-controlled trials and implications for nocebo-associated discontinuation of anti-osteoporotic drugs in clinical practice
12. Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece
13. Understanding frontal lobe function in epilepsy: Juvenile myoclonic epilepsy vs. frontal lobe epilepsy
14. Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression
15. Unveiling GFAP Astrocytopathy: Insights from Case Studies and a Comprehensive Review of the Literature.
16. Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review
17. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
18. COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study
19. Migraine: integrated approaches to clinical management and emerging treatments
20. Nocebo in Headache Treatment
21. Implications of Placebos and Nocebos in Clinical Practice
22. Definition of Refractory Chronic Headache
23. Diagnosis and management of migraine in ten steps
24. Validity and reliability of the Greek version of the neurogenic bladder symptom score (NBSS) questionnaire in a sample of Greek patients with multiple sclerosis
25. Galcanezumab add-on in refractory cluster headache. A case series.
26. Safety, Tolerability, and Nocebo Phenomena During Transcranial Magnetic Stimulation: A Systematic Review and Meta-Analysis of Placebo-Controlled Clinical Trials
27. Galcanezumab Add-on in Refractory Cluster Headache
28. Reply to the letter: Headaches during/after SARS‐CoV‐2 infection/vaccination can be primary and secondary as well as acute and chronic, by Finsterer J and Mehri S
29. Current and Emerging Treatment Options in Pediatric Onset Multiple Sclerosis
30. Depression and Anxiety Symptoms in Headache Disorders: An Observational, Cross-Sectional Study
31. Placebo responses vary by route of administration in migraine prevention trials. What does this mean?
32. A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study
33. Lateralization of Insular Ischemic Stroke is Not Associated With Any Stroke Clinical Outcomes: The Athens Stroke Registry
34. Therapies targeting CGRP signaling for medication overuse headache
35. Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures:post hoc analysis of the DELIVER randomized clinical trial
36. The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution:from headache burden to a global action plan for headache disorders
37. Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
38. IncobotulinumtoxinA for the Treatment of Blepharospasm in Toxin-Naïve Subjects: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial
39. Current understanding and future perspectives of brain–heart–kidney axis in psoriatic arthritis
40. Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis
41. Analysis of HCRTR2, GNB3, and ADH4 Gene Polymorphisms in a Southeastern European Caucasian Cluster Headache Population
42. Headache and Pregnancy
43. New players in the preventive treatment of migraine
44. Tension-type headache
45. Nocebo in multiple sclerosis trials: A meta-analysis on oral and newer injectable disease-modifying treatments
46. Headaches and facial pain attributed to SARS‐CoV‐2 infection and vaccination: a systematic review
47. Nocebo-associated treatment discontinuation with subcutaneous anti-osteoporotic drugs. A systematic review and meta-analysis of placebo-arm dropouts in randomized-controlled trials
48. Instrumental Occlusal Analysis in Migraine Patients: A Quantitative Cross Sectional Study.
49. Onabotulinumtoxina in the Prevention of Migraine in Pediatric Population: A Systematic Review.
50. Impact of fremanezumab treatment on disability outcomes in patients with migraine and major depressive disorder: Results of the UNITE study
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.